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a b s t r a c t
Chronic refractory angina remains a common and debilitating condition for millions of people, with up to 30% of
patients experiencing persistent angina despite successful revascularization. We share our experience with the
implantation of a coronary sinus reducer in two complex CAD patients with refractory angina despite multiple
revascularization strategies and maximally tolerated medical therapy.
© 2022 Published by Elsevier Inc.

1. Introduction
Over the past several decades interventional cardiology has experienced extensive growth in the ability to treat high-risk coronary artery
disease (CAD). At the same time, improvements in medical therapy
have helped reduce progression of coronary atherosclerosis and stabilize plaque in ischemic heart disease. The combination of treatment modalities has beneﬁted patients with CAD with both stable and unstable
features. However, there is a reported 10–12 million patients in the
U.S. that have poor targets for coronary revascularization and suffer
from refractory angina despite best efforts with medical therapy [1].
These patients experience signiﬁcant reductions in quality of life, both
physically and emotionally. To date, treatment options including novel
therapeutic strategies such as transmyocardial laser revascularization,
enhanced external counterpulsation, extracorporeal shockwave therapy, spinal-cord stimulation, and cell-based or gene therapies have
shown limited clinical beneﬁt or remain under investigation. The coronary sinus reducer (CSR) was developed to address this dilemma, and
there is emerging evidence to support its use for patients with refractory angina [2]. The device increases CS pressure, resulting in redistribution of myocardial blood ﬂow into ischemic territories [3]. Despite

Abbreviations: AMI, Acute myocardial infarction; CABG, Coronary artery bypass
grafting; CAD, Coronary artery disease; CCS, Canadian Cardiovascular Society; COSIRA,
Coronary Sinus Reducer for Treatment of Refractory Angina; CSR, Coronary sinus
reducer; CTO, Chronic total occlusion; DES, Drug eluting stent; LAD, Left anterior
descending; LCX, Left circumﬂex; LIMA, Left internal mammary artery; LVEDP, Left
ventricular end diastolic pressure; MPA2, French multipurpose A2 catheter; OM3, Third
obtuse marginal; PCI, Percutaneous intervention; RCA, Right coronary artery.
⁎ Corresponding author at: Division of Cardiology, Henry Ford Heart & Vascular
Institute, 2799 W. Grand Blvd, Detroit, MI 48202, USA.
E-mail address: rgindi1@hfhs.org (R. Gindi).

promising ﬁndings, the device remains commercially unavailable in
the U.S. In this case series, we present two patients treated at our institution in the U.S. who suffered from premature CAD requiring multiple
interventions and subsequently developed angina refractory to optimal
medical therapy. Both patients safely received and signiﬁcantly
beneﬁted from placement of a CSR with FDA approval for compassionate use.
2. Learning objectives
• In patients with angina refractory to medical therapy, the CSR may be
a safe and effective treatment option.
• The CSR aims to improve refractory angina by creating a controlled
narrowing of the CS which increases CS venous pressure and redistributes blood from less ischemic subepicardium to the more ischemic
subendocardium.
• Studies have shown that 70–80% of patients with refractory angina
who undergo CSR implantation have an improvement in anginal
symptoms.
• The narrowing within the CS, and subsequently the pressure gradient,
is achieved 4–6 weeks after implantation.
3. Case reports
3.1. Case 1
Our ﬁrst patient is a 59-year-old male with insulin-dependent diabetes suffering from severe multivessel CAD. He had his ﬁrst acute myocardial infarction (AMI) in 2012, demonstrating diffuse high-grade
stenosis in the left anterior descending (LAD) and left circumﬂex
(LCx) arteries, as well as a chronic total occlusion (CTO) of the right
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February 2004. Over the subsequent decade, he suffered multiple AMIs
requiring multiple stents placed in the native LAD and LCx arteries with
ﬁndings of an occluded left internal mammary artery (LIMA), occluded
vein grafts to a diagonal branch and RCA; and patent vein graft to the
OM3. In January 2016, he presented with severe exertional angina refractory to medical therapy. He was found to have a LAD CTO, OM3
CTO, and moderate LCx disease; he underwent successful PCI of the
LAD CTO resulting in dramatic symptomatic improvement. Unfortunately, his angina progressed to CCS class 3 by October 2018, and was
found to have severe in-stent restenosis of multiple overlapping stents
in the proximal to distal LAD (Fig. 1B, Videos 5-6). He was on maximally
tolerated medical therapy that included diltiazem 180 mg daily,
isosorbide-mononitrate 60 mg daily, ranolazine 500 mg twice daily,
and nitroglycerin 0.4 mg sublingual as needed. Beta-blocker therapy
was not tolerated. An exercise echocardiogram revealed ischemia in
LAD and LCx distributions after maximal exercise. Cardiopulmonary exercise testing revealed a peak VO2 of 18.4 mL/kg/min. Given poor targets for revascularization, the FDA was petitioned to implant a CSR for
compassionate use. Following FDA approval, the CSR was successfully
implanted without complication (Fig. 2B, Videos 7-8). Cardiopulmonary
exercise testing one month following CSR implantation showed peak
VO2 of 19.5 mL/kg/min. At one year follow up the patient reported
CCS class I symptoms. He described being able to ride a bicycle 35miles on hilly terrain without angina.

coronary artery (RCA). Given the diffuse and severe nature of disease, he
had poor surgical options for revascularization. He was initially treated
at an outside institution with PCI to the RCA using multiple stents, and
medically managed for this LAD and LCx disease. In April 2016, he suffered another AMI that was treated with balloon angioplasty to the
mid-RCA stent and a drug-eluting stent (DES) in the third obtuse marginal (OM3). The mid-distal LAD was subtotally occluded. He subsequently underwent multiple interventions to the LCx and OMs
without relief of angina. A nuclear viability study in June 2016 demonstrated a large area of hibernating myocardium in the LAD distribution,
and he underwent complex CTO PCI of the LAD with placement of multiple drug-eluting stents. Unfortunately, he suffered severe in-stent restenosis of the mid-LAD shortly after, requiring rotational atherectomy
and placement of another DES. He did well for 6 months, but had recurrence of debilitating angina refractory to medications, and was found to
have severe in-stent restenosis of the mid-LAD. He was treated with
brachytherapy and responded well for 6 months before having recurrence of severe angina. He unfortunately was found to again demonstrate diffuse severe in-stent restenosis with occlusion of the proximal
LAD (Fig. 1A, Videos 1-2). He was on maximally tolerated medical therapy including ranolazine 1000 mg twice daily, metoprolol tartrate
100 mg twice daily, isosorbide-mononitrate 30 mg daily and nitroglycerin 0.4 mg sublingual as needed. At this point, the FDA was petitioned
to use the CSR for compassionate use. He underwent an exercise stress
echocardiogram in January 2018 that showed normal baseline left ventricular function with multivessel ischemia, most notable in the LAD distribution. He maintained CCS class III symptoms, suffering from angina
with activities of daily living. Following FDA approval for compassionate
use, the patient underwent successful placement of a CSR without complication (Fig. 2A, Videos 3-4). A cardiopulmonary exercise test was performed one month following CSR implantation, and the patient was able
to exercise for 12 min and 32 s with a peak VO2 20.7 mL/kg/min. SPECT
MPI continued to demonstrate evidence of anterior wall ischemia, but
the patient was largely asymptomatic and did not require any further
interventional therapy. At one-year follow up after device implantation,
the patient reported CCS class I symptoms. He described walking several
miles around Washington D.C. without angina.

4. Implantation of CSR
Both patients received pre-treatment with dual-antiplatelet therapy.
The procedure was performed under moderate conscious sedation. Following right internal jugular vein access, 70 units/kg of unfractionated
heparin was administered. In a left anterior oblique (30°) angle, the coronary sinus (CS) was engaged with a diagnostic 6 French Multipurpose
A2 catheter (MPA2). CS venography was performed for sizing, side
branch location, and identifying preferred site for implantation. The
ideal site is usually 2–4 cm distal to the CS ostium, avoiding side
branches; and sized to a 1.1:1.0 ratio (expanded device diameter:CS diameter). A 0.35″ Supra Core™ (Abbott Vascular, Abbott Park, IL) wire
was advanced through the MPA2 into the CS, and the MPA2 was removed. The Neovasc CSR was then delivered and positioned using a
preshaped 9 French guiding catheter. The CSR balloon was inﬂated to
4 atms for 2 min in the ﬁrst patient and to 6 atms for 65 s in the second
patient. Post-inﬂation venography was performed to verify sufﬁcient

3.2. Case 2
Our second patient is a 59-year-old male with a history of premature
3-vessel CAD who underwent coronary artery bypass grafting (CABG) in

Fig. 1. A. Coronary angiogram demonstrating recurrence of proximal-LAD in-stent restenosis in Patient #1.
B. Coronary angiogram demonstrating in-stent restenosis of multiple stents in the proximal to distal LAD in Patient #2.
2
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Fig. 2. A. Venograms of coronary sinus pre- and post-CSR implantation in Patient #1.
B: Venograms of coronary sinus pre-and post-CSR implantation in Patient #2.

signiﬁcant epicardial coronary artery stenosis, myocardial perfusion is
redistributed towards the subepicardial layers. This results in reduced
perfusion of the subendocardium during stress, causing ischemia, impaired contractility, and elevated LV end diastolic pressure (LVEDP) as
reﬂected by angina and shortness of breath (Fig. 3B) [5].
The CSR procedure is a contemporary variation of a surgery performed by Beck and Leighninger in the 1950s to restrict venous drainage
of the heart [6]. The CSR is a stainless-steel, balloon-expandable hourglass shaped device able to be percutaneously implanted in the CS. By
implanting a CSR, backward pressure in the coronary venous system results in dilation of arterioles, reduction of vascular resistance in the
subendocardium, and improved blood ﬂow (Fig. 3C) [3]. The Coronary
Sinus Reducer for Treatment of Refractory Angina (COSIRA) trial was
an international phase 2 multicenter, randomized, double-blind,
sham-controlled trial that showed CSR implantation in patients with refractory angina resulted in signiﬁcant improvement in quality of life and
reduction in Canadian Cardiovascular Society (CCS) score [2]. Although
not currently commercially available in the U.S., providers may petition
the FDA for approval for compassionate use. The process includes demonstrating that the patient has undergone all other available approved
treatment options, while still suffering from life-threatening or lifealtering angina. Patient protection measures such as written consent

oversizing. Procedural time was 57 min and 39 min, respectively.
Neither patient had any vascular complications involving the CS or venous access sites, with no device embolization, thrombosis, or dissection. Dual-antiplatelet therapy was maintained in both patients for
6 months, as well as continued anti-anginal medical therapies. Evidence
supporting the duration of DAPT post-CSR implantation is lacking,
however the 6 months of therapy used in COSIRA has been shown to
be safe.
5. Discussion
Chronic refractory angina remains a common and debilitating condition for millions of people, despite advancements in medical and interventional therapy. Clinical trials and registries have demonstrated that
20–30% of patients undergoing revascularization may continue to experience persistent angina despite initial successful revascularization [4].
This may be explained by the physiologic consequences of myocardial
ischemia. Normally, blood ﬂow in the subendocardial myocardium is
higher than in the subepicardial layers (Fig. 3A), and during exercise
there is selective sympathetic-mediated vasoconstriction of the subepicardial vessels causing an increased subendocardial perfusion and augmentation of myocardial contractility. However, when there is
3
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Fig. 3. A. In a non-ischemic heart, blood ﬂow in the subendocardium is higher than in the subepicardium, and during exercise there is selective sympathetic-mediated vasoconstriction of
the subepicardial vessels causing further increased subendocardial perfusion and augmentation of myocardial contractility.
B. In an ischemic heart, there is signiﬁcant epicardial coronary artery stenosis so myocardial perfusion is redistributed towards the subpicardial layers resulting in reduced perfusion of
subendocardium during stress. This reduced perfusion results in ischemia, impaired contractility, and elevated LVEDP.
C. The presence of a CSR results in backward pressure in the coronary venous system, resulting in dilation of arterioles, reduction of vascular resistance in the subendocardium, and
improved blood ﬂow.

a follow-up report must be submitted to the FDA within 45 days of
using the device with patient outcome and any potential problems [7].
Our ﬁrst patient had undergone multiple PCIs without surgical options, and our second patient had surgical revascularization followed

from the patient, clearance from the institution, and an independent assessment of an uninvolved physician must be obtained. The physicians
must then contact the medical device company for agreement to provide the CSR device under compassionate use. Following implantation,
4
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by multiple PCIs. Both patients were on ﬁrst-, second- and third-line
medical therapy, but continued to have debilitating angina. Following
implantation of CSR, both patients had an improvement of two CCS classes. Our outcomes were similar to what was shown in the COSIRA trial,
which showed that 35% of patients with refractory angina had an improvement of at least two CCS classes with CSR implantation, as compared to 15% in the control group at 6 months. Furthermore, there
was an improvement of at least one CCS class in 71% of the patients in
the CSR group. Extending to real-world cohorts, Abawi et al. in the
Netherlands [8] and Giannini et al. in Italy [9] demonstrated clinical
safety and efﬁcacy comparable to the COSIRA trial. Most recently, the
Dutch shared their 5-year experience regarding the safety and efﬁcacy
of the CSR following implantation of 132 patients with refractory angina
and the results were impressive; the CSR successfully implanted in 99%
of patients and the mean CCS class improved from 3.17 ± 0.61 to
2.12 ± 1.07 (p < 0.001) [10]. The CSR has Conformitè Europëenne
(CE) mark and is currently available in Europe and the Middle East,
but has yet to be FDA approved in the U.S. The COSIRA-II IDE trial was
FDA approved in November 2017 as a pivotal U.S. trial to further demonstrate safety and effectiveness of the device, and the Reducer Device
received Breakthrough Device Designation with the FDA in 2018. Cost
related issues and additional logistics have hampered the initiation of
the trial to date, however the trial is expected to begin enrolling patients
in early 2022.
We share our experience with two complex CAD patients with refractory angina and demonstrable ischemia despite multiple revascularization strategies and maximally tolerated medical therapy. At one-year
post-CSR implantation, both patients reported a sustained improvement of two CCS classes. Our results continue to support the potential
beneﬁts of the CSR as an adjunctive therapy in refractory angina.

approval for compassionate use to reduce angina, myocardial ischemia,
and improve quality of life.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.carrev.2022.01.003.
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6. Conclusion
In patients with angina refractory to medical therapy and percutaneous ± surgical intervention, the CSR can be implanted through FDA
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